TOP > 外国特許検索 > SCREENING METHOD UTILIZING THALIDOMIDE-TARGETING FACTOR

SCREENING METHOD UTILIZING THALIDOMIDE-TARGETING FACTOR

外国特許コード F120006576
掲載日 2012年5月14日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2010JP068272
国際公開番号 WO 2011049043
国際出願日 平成22年10月18日(2010.10.18)
国際公開日 平成23年4月28日(2011.4.28)
優先権データ
  • 特願2009-241290 (2009.10.20) JP
発明の名称 (英語) SCREENING METHOD UTILIZING THALIDOMIDE-TARGETING FACTOR
発明の概要(英語) Disclosed is a means for developing a compound which has no teratogenicity while retaining a useful activity. Specifically disclosed is a method for screening for a non-teratogenic substance, which is characterized by comprising: bringing each of test substances into contact with cerebron or a fragment thereof; evaluating the bindability of the test substances to cerebron or the fragment thereof; and selecting a test substance that does not bind to cereblon or the fragment thereof or a test substance that has lower bindability to cereblon or the fragment thereof compared to that of thalidomide.
従来技術、競合技術の概要(英語) BACKGROUND ART
1950 To the beginning of year 60 since the latter half, more than 40 as a sedative thalidomide is sold in the country, it is also possible for the prevention of morning sickness during pregnancy women often formulated. Teratogenic risk of thalidomide to which notable, to the stop of its use include stillbirths several thousand -1 (morphogenic disorder) deformity exceeds ten million estimated to have occurred (Japanese Unexamined Patent Publication 1-3). 3-8 weeks pregnant women and the dose thereof, referred to as embryo thalidomide fetus's limb, ear, heart, digestive organ lesion formed in the embodiment (Reference 1-3). Among them the limb, a significant frequency of the ear. Fokomeria known as a malfunction of the limbs (phocomelia), the shorter arm or foot-characterized, is performed for each ear of the ear-free treatment of osteoarthritis and overheard, typified by a hearing loss. To elucidate the cause of the considerable efforts have been made in spite of, the development defects to be known for a few. Oxidative stress induced by previous research thereof having angiogenesis inhibiting effect and have been found, it may be as in the cause of the teratogenicity (Japanese Unexamined Patent Publication 4-5). However, several important question is left behind. That is, the direct target of any molecule, as to how the target agents or teratogenicity that is responsible for the property.
Incidentally, as a candidate agent that causes the human mild CRBN the spirit of the protein is known (Non-Patent Document 1, Patent Document 11). This protein, the protein can be bound to the Damaged DNA Binding protein 1(DDB1) is also reported (Non-Patent Document 2, Patent Document 12), the relevance of thalidomide is no report about how.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • Tokyo Institute of Technology
  • Fujimoto Pharmaceutical Corporation
  • 発明者(英語)
  • HANDA, Hiroshi
  • ANDO, Hideki
  • ITOH, Takumi
  • HOTTA, Kentaro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
詳しくお知りになりたい方は下記「問合せ先」まで直接お問合わせください

PAGE TOP

close
close
close
close
close
close